Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)

Ronald H. Blum; Joseph M. Corson; Richard E. Wilson; Joel S. Greenberger; George P. Canellos; Emil Frei

doi:10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M

Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)

Ronald H. Blum
, Joseph M. Corson
, Richard E. Wilson
, Joel S. Greenberger
, George P. Canellos
, Emil Frei

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m²) on day 1, cyclophosphamide (500 mg/m²) on day 2, and DTIC (400 mg/m²) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm³. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.

Original language	English
Pages (from-to)	1722-1726
Number of pages	5
Journal	Cancer
Volume	46
Issue number	8
DOIs	https://doi.org/10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M
State	Published - 15 Oct 1980
Externally published	Yes

Access to Document

10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M

Cite this

@article{e0ba3fcb06044bce95e1fdab587e3ced,

title = "Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)",

abstract = "Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m2) on day 1, cyclophosphamide (500 mg/m2) on day 2, and DTIC (400 mg/m2) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17\%) had a complete response, 9 patients (39\%) had a partial response, 5 patients (22\%) had stabilization, but 5 patients (22\%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm3. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.",

author = "Blum, \{Ronald H.\} and Corson, \{Joseph M.\} and Wilson, \{Richard E.\} and Greenberger, \{Joel S.\} and Canellos, \{George P.\} and Emil Frei",

year = "1980",

month = oct,

day = "15",

doi = "10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M",

language = "English",

volume = "46",

pages = "1722--1726",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)

AU - Blum, Ronald H.

AU - Corson, Joseph M.

AU - Wilson, Richard E.

AU - Greenberger, Joel S.

AU - Canellos, George P.

AU - Frei, Emil

PY - 1980/10/15

Y1 - 1980/10/15

N2 - Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m2) on day 1, cyclophosphamide (500 mg/m2) on day 2, and DTIC (400 mg/m2) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm3. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.

AB - Fifty consecutive adults with sarcoma were treated with Adriamycin (45 mg/m2) on day 1, cyclophosphamide (500 mg/m2) on day 2, and DTIC (400 mg/m2) on days 1 and 2 (CAD). Of the 23 patients with measurable metastatic disease, 4 patients (17%) had a complete response, 9 patients (39%) had a partial response, 5 patients (22%) had stabilization, but 5 patients (22%) did not respond. The actuarial survival of complete and partial responders was 31.5 months compared to 5.5 months for non‐responders (P < .005). Chemotherapy doses were escalated to a median lowest white count of 700 cells/mm3. Acute gastrointestinal toxicity and alopecia occurred in all patients. CAD differed from previously reported combinations by omission of vincristine, a two‐day dose schedule and dose rate intensification. CAD is recommended for patients with metastatic sarcoma.

UR - https://www.scopus.com/pages/publications/0018926814

U2 - 10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M

DO - 10.1002/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M

M3 - Article

C2 - 7427876

AN - SCOPUS:0018926814

SN - 0008-543X

VL - 46

SP - 1722

EP - 1726

JO - Cancer

JF - Cancer

IS - 8

ER -

Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD)

Abstract

Access to Document

Fingerprint

Cite this